ArticleJournal of advanced research2026
Engineering a multifunctional nanoplatform with cascade catalytic and bidirectional immunomodulatory capacities for integrating sepsis therapy.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-Assembled Carrier-Free Nanostructures of Anemoside B4 and Oleanolic Acid Alleviate Intestinal Injury Induced by IntraperitonealAntioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated immune response to infection. Despite extensive research into its complex pathogenesis, effective clinical treatments remain limited, necessitating novel therapeutic strategies.
objectivesThis study aims to develop a multifunctional nanozyme-based therapy for severe sepsis, combining broad-spectrum antimicrobial activity and reactive oxygen species (ROS) scavenging to counteract organ injury, immune dysregulation, and high mortality.
methodsWe designed biocompatible resveratrol-Ag + -Prussian blue nanozymes (ARPB NZs) and evaluated their therapeutic effects in two murine sepsis models: E. coli-induced abdominal infection and cecal ligation puncture (CLP). Mechanistic studies focused on oxidative stress attenuation, cytokine storm suppression, lymphocyte function, and dendritic cell pyroptosis via the NLRP3/caspase-1/GSDMD pathway.
resultsARPB NZs effectively alleviated organ damage, maintained immune homeostasis by reducing inflammation and oxidative stress, and significantly improved survival rates in both sepsis models. They also inhibited lymphocyte apoptosis and dampened dendritic cell pyroptosis.
conclusionARPB NZs represent a promising synergistic strategy for severe sepsis by simultaneously targeting infection and immune dysregulation. This approach may translate into broader applications for infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.